Mirum Pharmaceuticals, Inc. (MIRM)
NASDAQ: MIRM · Real-Time Price · USD
90.00
+2.20 (2.51%)
Mar 4, 2026, 11:50 AM EST - Market open
Mirum Pharmaceuticals Employees
As of December 31, 2025, Mirum Pharmaceuticals had 372 total employees, including 369 full-time and 3 part-time employees. The number of employees increased by 50 or 15.53% compared to the previous year.
Employees
372
Change
50
Growth
15.53%
Revenue / Employee
$1,401,376
Profits / Employee
-$62,804
Market Cap
5.43B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 372 | 50 | 15.53% | 369 | 3 |
| Sep 30, 2025 | 355 | 44 | 14.15% | 355 | 0 |
| Jun 30, 2025 | 349 | 55 | 18.71% | 349 | 0 |
| Mar 31, 2025 | 334 | 56 | 20.14% | 334 | 0 |
| Dec 31, 2024 | 322 | 58 | 21.97% | 322 | 0 |
| Sep 30, 2024 | 311 | 62 | 24.90% | 311 | 0 |
| Jun 30, 2024 | 294 | 81 | 38.03% | 294 | 0 |
| Mar 31, 2024 | 278 | 78 | 39.00% | 278 | 0 |
| Dec 31, 2023 | 264 | 68 | 34.69% | 264 | 0 |
| Sep 30, 2023 | 249 | 55 | 28.35% | 249 | 0 |
| Jun 30, 2023 | 213 | 42 | 24.56% | 213 | 0 |
| Mar 31, 2023 | 200 | 56 | 38.89% | 200 | 0 |
| Dec 31, 2022 | 196 | 59 | 43.07% | 196 | 0 |
| Sep 30, 2022 | 194 | 57 | 41.61% | 194 | 0 |
| Jun 30, 2022 | 171 | 51 | 42.50% | 171 | 0 |
| Mar 31, 2022 | 144 | 59 | 69.41% | 144 | 0 |
| Dec 31, 2021 | 137 | 69 | 101.47% | 137 | 0 |
| Sep 30, 2021 | 137 | 70 | 104.48% | 137 | 0 |
| Jun 30, 2021 | 120 | 66 | 122.22% | 120 | 0 |
| Mar 31, 2021 | 85 | 44 | 107.32% | 85 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Caris Life Sciences | 1,769 |
| PTC Therapeutics | 991 |
| Rhythm Pharmaceuticals | 414 |
| CRISPR Therapeutics AG | 393 |
| Immunovant | 362 |
| Cogent Biosciences | 258 |
| Apogee Therapeutics | 196 |
| CG Oncology | 142 |
MIRM News
- 6 days ago - Mirum Pharmaceuticals, Inc. (MIRM) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 6 days ago - Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2025 Results and Provides Business Update - Business Wire
- 8 days ago - Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences - Business Wire
- 13 days ago - Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2025 Financial Results and Host Conference Call on February 25, 2026 - Business Wire
- 21 days ago - Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 27 days ago - Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® Tablet Formulation for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome - Business Wire
- 27 days ago - Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® for the Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis (PFIC) - Business Wire
- 4 weeks ago - Top 3 Health Care Stocks That May Implode In Q1 - Benzinga